Munro R A, Sturrock R D
University Department of Medicine, Glasgow Royal Infirmary University NHS Trust, Scotland.
Drug Saf. 1995 Jul;13(1):25-30. doi: 10.2165/00002018-199513010-00004.
The slow-acting antirheumatic drugs (SAARDs) are being used in an increasing proportion of patients with rheumatoid arthritis (RA). The potential toxicity of each drug is well recognised. Many patients with RA will be on other medications and the potential for adverse drug interactions with SAARDs is not so well publicised. There have, over the years, been numerous reports of possible drug interactions with SAARDs but few of these are clinically relevant. It is, however, vitally important that the physician is aware of a number of potentially life-threatening interactions, particularly those associated with methotrexate. The SAARDs are a very useful group of drugs for the treatment of RA and, by being aware of their potential toxicity and drug interactions, hopefully they can be used safely and effectively.
越来越多的类风湿关节炎（RA）患者正在使用慢作用抗风湿药物（SAARDs）。每种药物的潜在毒性已得到充分认识。许多RA患者还会服用其他药物，而SAARDs与其他药物发生不良相互作用的可能性却没有得到广泛宣传。多年来，有许多关于SAARDs可能发生药物相互作用的报道，但其中很少有具有临床相关性的。然而，医生了解一些潜在的危及生命的相互作用至关重要，尤其是与甲氨蝶呤相关的相互作用。SAARDs是治疗RA的非常有用的一类药物，通过了解其潜在毒性和药物相互作用，有望能安全有效地使用它们。
